- Home
- PAYS vs SKYE Comparison
PAYS vs SKYE Comparison
Compare PAYS & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYS
- SKYE
- Stock Information
- Founded
- PAYS 2001
- SKYE 2012
- Country
- PAYS United States
- SKYE United States
- Employees
- PAYS N/A
- SKYE N/A
- Industry
- PAYS Business Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- PAYS Consumer Discretionary
- SKYE Health Care
- Exchange
- PAYS Nasdaq
- SKYE Nasdaq
- Market Cap
- PAYS 125.2M
- SKYE 115.9M
- IPO Year
- PAYS 1998
- SKYE N/A
- Fundamental
- Price
- PAYS $7.88
- SKYE $3.98
- Analyst Decision
- PAYS Strong Buy
- SKYE Buy
- Analyst Count
- PAYS 4
- SKYE 6
- Target Price
- PAYS $7.06
- SKYE $16.60
- AVG Volume (30 Days)
- PAYS 1.1M
- SKYE 2.2M
- Earning Date
- PAYS 08-05-2025
- SKYE 08-08-2025
- Dividend Yield
- PAYS N/A
- SKYE N/A
- EPS Growth
- PAYS N/A
- SKYE N/A
- EPS
- PAYS 0.11
- SKYE N/A
- Revenue
- PAYS $63,792,627.00
- SKYE N/A
- Revenue This Year
- PAYS $30.03
- SKYE N/A
- Revenue Next Year
- PAYS $20.14
- SKYE N/A
- P/E Ratio
- PAYS $71.65
- SKYE N/A
- Revenue Growth
- PAYS 26.77
- SKYE N/A
- 52 Week Low
- PAYS $1.80
- SKYE $1.14
- 52 Week High
- PAYS $8.57
- SKYE $7.47
- Technical
- Relative Strength Index (RSI)
- PAYS 85.08
- SKYE 60.88
- Support Level
- PAYS $4.72
- SKYE $3.65
- Resistance Level
- PAYS $8.57
- SKYE $4.75
- Average True Range (ATR)
- PAYS 0.50
- SKYE 0.71
- MACD
- PAYS 0.12
- SKYE 0.00
- Stochastic Oscillator
- PAYS 95.89
- SKYE 48.55
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.